OneSource Specialty Pharma has achieved a significant regulatory milestone with its flagship manufacturing unit in Bengaluru receiving Good Manufacturing Practices (GMP) certification from ANVISA, Brazil’s premier health authority. The approval follows a successful inspection conducted in November 2024 and positions the company to expand into one of the world’s largest pharmaceutical markets. This development is especially timely as Brazil prepares to welcome generic versions of Semaglutide, a blockbuster drug category.